Retinopathy of Prematurity (Retrolental Fibroplasia)

Subscribe to Selected New Research on Retinopathy of Prematurity

2010 relevant articles (99 outcomes, 265 trials/studies) found for this Disease

Description: A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)

Also Known As:

Retrolental Fibroplasia; Fibroplasia, Retrolental; Fibroplasias, Retrolental; Prematurity Retinopathies; Prematurity Retinopathy; Retrolental Fibroplasias

Relationship Network

Disease Context: Research Results

Eye Diseases: 1323

Retinal Diseases: 702

Retinopathy of Prematurity: 2010

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 449

Diseases Newborn Infant

Diseases Premature Infant

Retinopathy of Prematurity: 2010

Related Diseases

1.	Retinal Detachment (Retinal Detachments)
2.	Birth Weight (Birth Weights)
3.	Blindness (Hysterical Blindness)
4.	Hemorrhage
5.	Diabetic Retinopathy (Retinopathy, Diabetic)

Experts

1.	Trese, Michael T: 8 articles (06/2008 - 09/2002)
2.	Smith, Lois E H: 7 articles (06/2008 - 07/2003)
3.	Phelps, Dale L: 7 articles (07/2006 - 09/2002)
4.	Cryotherapy for Retinopathy of Prematurity Cooperative Group: 7 articles (02/2006 - 02/2001)
5.	Quinn, Graham E: 6 articles (06/2008 - 11/2002)
6.	Dobson, Velma: 6 articles (04/2007 - 11/2002)
7.	Holz, Eric R: 6 articles (09/2006 - 10/2004)
8.	Capone, Antonio: 5 articles (06/2008 - 09/2002)
9.	Tasman, William: 5 articles (04/2008 - 05/2002)
10.	Hartnett, M Elizabeth: 5 articles (04/2008 - 04/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Retinopathy of Prematurity:

1.	ROPIBA 01/01/2008 - "With improved survival of very low birth infants in India, Retinopathy of Prematurity (ROP) is emerging as a significant problem. " 09/01/1996 - "BACKGROUND: Retinopathy of prematurity (RoP) has become more common in developed countries with an improvement in survival of very premature infants. " 01/01/1989 - "Retinopathy of prematurity (ROP) is attracting renewed interest from ophthalmologists and neonatologists because of the improved survival of very low birthweight premature infants, some of whom develop blinding disease. " 01/01/1989 - "The fact that the average ROP prevalence has not changed significantly indicates that the risk of having retinopathy of prematurity has switched over to the more immature preterms, whose prognosis of survival has improved in the last few years as a result of the improvement in neonatal care." 04/01/2009 - "PURPOSE OF REVIEW: This review will discuss a potentially more effective treatment for retinopathy of prematurity (ROP) with fewer acute and long-term complications. " Order ALL the reference details at left...
2.	Retinaldehyde (Retinal)IBA 01/01/2009 - "BACKGROUND: The Early Treatment for Retinopathy of Prematurity trial demonstrated that peripheral retinal ablation of eyes with high-risk prethreshold retinopathy of prematurity (early treatment) is associated with improved visual outcomes at 9 months' corrected gestational age compared with treatment at threshold disease (conventional management). " 12/01/2003 - "In comparison, in the presence of the retinal shortening and folding that develops postnatally in retinopathy of prematurity, familial exudative vitreoretinopathy, and incontinentia pigment, spontaneous release of the shortening can be expected following surgical removal of the preretinal fibrous tissue, and associated encircling procedures can be effective in selected cases. " 05/01/2003 - "These results provide a framework for study of retinal vascular development, validate the common use of perinatal retinal models in angiogenesis research, and clarify the cellular basis of retinopathy of prematurity." 07/01/1985 - "In general, this study demonstrates important similarities between canine and human retinal vascular development, and this gives further reason to use of the puppy retina as a superior model for studying retrolental fibroplasia pathogenesis. " 05/01/2009 - "Fundus examination with escleral depression was first carried out between the 3rd and 8th weeks after birth and repeated every 1 to 4 weeks depending on the retinal imaging findings, until retina vascularization was complete or retinopathy of prematurity was present and it was followed by an annual ophthalmologic follow-up comprised of fundus examination and refraction. " Order ALL the reference details at left...
3.	Vitamin E FDA Link 05/01/1990 - "Analysis of nine randomised controlled trials of prophylactic vitamin E supplementation in very low-birthweight infants (less than 1500g) showed no statistically significant reduction in the incidence of acute retinopathy of prematurity. " 10/01/1999 - "Extensive research on the use of vitamin E for the prevention of retrolental fibroplasia (retinopathy of the newborn), despite yielding promising results, has not resulted in incorporation of vitamin E into conventional standards of care protocols. " 12/03/1981 - "Retrolental fibroplasia: efficacy of vitamin E in a double-blind clinical study of preterm infants." 01/01/2006 - "These include vitamin E as a prophylaxis against retinopathy of prematurity and the efficacy of light reduction to prevent retinopathy of prematurity. " 05/01/1986 - "The efficacy of vitamin E in retinopathy of prematurity." Order ALL the reference details at left...
4.	OxygenIBA 06/01/1960 - "A case of retrolental fibroplasia, treated and cured with administration of oxygen in alternating concentrations." 07/01/2006 - "Influence of prior assignment on refusal rates in a trial of supplemental oxygen for retinopathy of prematurity." 04/01/2005 - "In the multicenter Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity trial, all infants had some degree of pulmonary dysfunction, because eligibility required a median oxygen saturation of < or =94% with room air. " 09/01/2002 - "Retinopathy of prematurity outcome in infants with prethreshold retinopathy of prematurity and oxygen saturation >94% in room air: the high oxygen percentage in retinopathy of prematurity study." 12/01/2001 - "By the mid 1950s, new information linking oxygen therapy and retrolental fibroplasia, led to a rapid decline in the use of the AL, even before the publication of the randomized trial." Order ALL the reference details at left...
5.	bevacizumab FDA Link 11/01/2008 - "Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study." 10/01/2009 - "A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity." 04/01/2009 - "Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II." 04/01/2009 - "Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II." 02/01/2009 - "Off-label use of bevacizumab in retinopathy of prematurity." Order ALL the reference details at left...
6.	Fluorescein (Funduscein)FDA LinkGeneric 01/01/2008 - "PURPOSE: To study the role of intravenous fluorescein angiography in early detection and regression of retinopathy of prematurity. " 10/01/1976 - "[Fluorescein angiographic studies on retinopathy of prematurity (author's transl)]" 07/01/2009 - "Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography." 01/01/2008 - "CONCLUSIONS: Retcam-assisted intravenous fluorescein angiography is safe and helps in the early diagnosis, prompt management, and complete regression of retinopathy of prematurity." 01/01/2008 - "Role of intravenous fluorescein angiography in early detection and regression of retinopathy of prematurity." Order ALL the reference details at left...
7.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/01/2008 - "PURPOSE: To study the effects of a neutralizing antibody to vascular endothelial growth factor (VEGF), given as an intravitreous injection, on intravitreous neovascularization (IVNV) and ongoing vascular development of avascular retina in a rat model relevant to human retinopathy of prematurity. " 07/01/2009 - "Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity." 06/01/2009 - "Lack of association of VEGF (-2578 C-->A) and ANG 2 (-35 G-->C) gene polymorphisms with the progression of retinopathy of prematurity." 11/01/2008 - "Anti-vascular endothelial growth factor and retinopathy of prematurity." 10/01/2008 - "The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity." Order ALL the reference details at left...
8.	Insulin-Like Growth Factor I (IGF-1)IBA 07/01/2002 - "Experimental and clinical studies suggest that GH and IGF-I may be involved in neovascularization of the retina in diabetes and retinopathy of prematurity. " 12/01/2006 - "Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity." 04/01/2005 - "[Serum IGF-I levels in retinopathy of prematurity. " 01/01/2005 - "IGF-1 and retinopathy of prematurity in the preterm infant." 12/01/2001 - "In conclusion, persistent low serum IGF-I levels may explain the slow physical growth during neonatal life, and exposure of high GH may cause, at least in part, severe retinopathy of prematurity in preterm infants." Order ALL the reference details at left...
9.	ArgonIBA 03/01/2006 - "METHODS: This is a descriptive, observational, longitudinal and prospective study carried out from March 1991 to February 2005, including patients with threshold retinopathy of prematurity for treatment using Argon laser under indirect ophthalmoscopy. " 03/01/2006 - "[Evolution of threshold retinopathy of prematurity after argon laser treatment under indirect ophthalmoscopy]" 05/15/1992 - "Transient punctate lenticular opacities as a complication of argon laser photoablation in an infant with retinopathy of prematurity." 11/01/2005 - "Argon laser photocoagulation for retinopathy of prematurity: long-term outcome." 09/01/1997 - "Acute serous detachment with argon laser photocoagulation in retinopathy of prematurity." Order ALL the reference details at left...
10.	Sucrose (Saccharose)IBA 12/01/2004 - "Analgesic effects of oral sucrose and pacifier during eye examinations for retinopathy of prematurity." 06/01/2005 - "Efficacy of sucrose to reduce pain in premature infants during eye examinations for retinopathy of prematurity." 05/01/2006 - "Sucrose and non-nutritive sucking for the relief of pain in screening for retinopathy of prematurity: a randomised controlled trial." 12/01/2004 - "Oral sucrose reduces pain during heel sticks and venipunctures in preterm infants, but no studies have been done to determine the effectiveness of sucrose during eye examinations for retinopathy of prematurity. " 01/01/2005 - "Can oral sucrose reduce the pain and distress associated with screening for retinopathy of prematurity?" Order ALL the reference details at left...

Therapies and Procedures

1.	Cryotherapy (Therapy, Cold) 03/01/1991 - "Cryotherapy has been shown to be an effective treatment for retinopathy of prematurity stage 3. It is said to reduce the unfavourable outcome of the disease by 50%. " 05/01/1989 - "Cryotherapy: a new treatment for retinopathy of prematurity." 06/01/1992 - "Efficacy of cryotherapy for retinopathy of prematurity." 05/01/1992 - "The Multicenter Trial of Cryotherapy for Retinopathy of Prematurity previously reported reduced incidence of both poor structural and functional outcomes after cryotherapy. " 02/01/1990 - "These data, together with numerous additional ocular findings and preliminary 12-month postrandomization outcome results reported herein, support the efficacy of cryotherapy in reducing the risk of unfavorable ocular outcome from threshold retinopathy of prematurity. " Order ALL the reference details at left...
2.	Light Coagulation 09/01/1971 - "[Clinical study and photocoagulation of retinopathy of prematurity]" 06/01/2007 - "Quantitative analysis of retinal vessel diameter reduction after photocoagulation treatment for retinopathy of prematurity." 01/01/2004 - "Risk factors for retinopathy of prematurity requiring photocoagulation." 11/01/1997 - "Overtreatment should be carefully avoided in zone I retinopathy of prematurity and zone II retinopathy with signs of possible rapid progression, which requires photocoagulation inside the vascular arcade." 06/01/1997 - "Overtreatment should be carefully avoided in retinopathy of prematurity complicated by disease in which photocoagulation needs to be done in the area posterior to the ridge." Order ALL the reference details at left...
3.	Semiconductor Lasers 03/01/2000 - "CONCLUSION: In this population of infants, diode laser ablation appears to be a safe and effective treatment for threshold retinopathy of prematurity." 01/01/2006 - "PURPOSE: The aim of this study was to analyze risk factors influencing diode laser treatment of active phase of retinopathy of prematurity. " 01/01/2000 - "AIM: The purpose of the study was to assess the outcomes of the diode laser in the treatment of retinopathy of prematurity and to discuss the up-to-date possibilities of treating of active phase of this disease. " 06/01/2008 - "[New anaesthetic technique in diode laser treatment of retinopathy of prematurity]" 06/01/2008 - "Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes." Order ALL the reference details at left...
4.	Lasers (Laser) 06/01/2008 - "Neonates treated after December 2003 (cutoff date of the Early Treatment of Retinopathy of Prematurity study) underwent a significantly greater number of laser applications (mean +/- SD, 2,286 +/- 1,087) than did neonates treated earlier. " 03/01/2008 - "Study population: Premature infants in the Neonatal ward requiring laser treatment for threshold retinopathy of prematurity. " 01/01/1999 - "This rate was higher than predicted if fellow-eye outcomes were truly independent (P < .00001) and did not depend on study center, laser settings, or location of the retinopathy of prematurity. " 04/01/2009 - "Cost-utility analysis of screening and laser treatment of retinopathy of prematurity." 04/01/2009 - "BACKGROUND: Plus disease is the major criterion for laser treatment of retinopathy of prematurity. " Order ALL the reference details at left...
5.	Vitrectomy 09/01/1995 - "PURPOSE: This study was done to determine the efficacy of closed vitrectomy on long-term visual acuity of stage 5 retinopathy of prematurity. " 07/01/2009 - "Functional and anatomical outcomes after primary lens-sparing pars plana vitrectomy for Stage 4 retinopathy of prematurity." 10/01/2008 - "Pre-operative intraocular pressure in retinopathy of prematurity patients is unknown, but intraocular pressure during vitrectomy is elevated, and likely elevated postoperatively. " 04/01/2008 - "Three-year anatomic and visual outcomes after vitrectomy for stage 4B retinopathy of prematurity." 03/01/2008 - "25-gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Retinopathy of Prematurity

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 99 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>